blood

PreclinicalBiologic

UUniversity Hospital, Lille

blood is one of 111 biologic programs targeting Rheumatoid Arthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Duodenal UlcerActive, not recruiting

Postpartum HemorrhageActive, not recruiting

Metastatic MelanomaCompleted

Stem CellsCompleted

Rheumatoid ArthritisPreclinical

Active, not recruiting

Duodenal UlcerPreclinical

Active, not recruiting

Postpartum HemorrhagePreclinical

Active, not recruiting

Metastatic MelanomaPreclinical

Completed

Stem CellsPreclinical

Completed

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actos

Takeda

Preclinical

2 2

Celexa

AbbVie

Preclinical

1 3

Voltaren

Cataflam

Plaquenil

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Nsaids

Roche

Preclinical

1 10

Pneumococcal Conjugate Vaccine

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Headache

NCT07354464

Q4 2030

Not yet recruiting

Immune

NCT06992531

Clinical

Trials by Indication[1]

Crohn's Disease1 trial

Search for New Genetic Mutations Major Effect in Crohn's Disease

Completed·UUniversity Hospital, Lille··NCT02851134·20 enrolled

Immune1 trial

Auto-immune Contribution in Symptom-based Sensory and Autonomic Disorders

Not yet recruiting·KKing's College London··NCT06992531·250 enrolled

Headache1 trial

Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches

Recruiting·UUniversity Hospital, Clermont-Ferrand·Phase 3·NCT07354464·80 enrolled

Postpartum Hemorrhage1 trial

Early Usage of Bakri Ballon in Managing Postpartum Hemorrhage

Completed·DDongyu Wang·N/A·NCT02861482·472 enrolled

Rheumatoid Arthritis1 trial

Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years

Completed·—··NCT02894047·42 enrolled

6 more indications

GAN1 trial

TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure

Completed·UUniversity Hospital, Lille··NCT03055169·994 enrolled

Duodenal Ulcer1 trial

Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers

Completed·ZZagazig University·N/A·NCT01560702·100 enrolled

Stem Cells1 trial

Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft

Completed·UUniversity Hospital, Lille·N/A·NCT03280290·20 enrolled

Alzheimer's Disease1 trial

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

Unknown status·—·N/A·NCT02811653·155 enrolled

Metastatic Melanoma1 trial

Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1).

Completed·HHospices Civils de Lyon·Preclinical·NCT03225365·5 enrolled

Unspecified2 trials

Effects of Transfusion of Older Stored Red Cells

Terminated·—·N/A·NCT01534676·3 enrolled

HES Patch Versus Blood Patch

Completed·UUniversity Hospital, Strasbourg, France·N/A·NCT02570724·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for blood. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — blood compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for blood. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Lille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Lille

blood

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2030

Trials by Indication[1]

Crohn's Disease1 trial

Immune1 trial

Headache1 trial

Postpartum Hemorrhage1 trial

Rheumatoid Arthritis1 trial

GAN1 trial

Duodenal Ulcer1 trial

Stem Cells1 trial

Alzheimer's Disease1 trial

Metastatic Melanoma1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News